Recent Updates
Recently added Catalysts

Meningococcal ABCWY

Phase 2

Meningococcal Disease | Monoclonal antibody | Other |GSK plc|Last Updated: Sep 24, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment189
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02285777Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy AdolescentsPHASE2 COMPLETED 189Dec 1, 2014Jun 11, 2015Sep 24, 20188 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentages of Subjects Without Bactericidal Activity at 1:4 Dilution Against Each US Neisseria Meningitides (N. Meningitidis) Serogroup B Strain at 1 Month After the 3-dose Vaccination Series.
At Month 7 (1 month after the 3-dose vaccination series)

The effectiveness of three doses of MenABCWY vaccine when compared to one dose of MenACWY vaccine against a panel of US N. meningitidis serogroup B invasive disease strains at 1 month after the 3-dose vaccination series was evaluated in terms of: the combined percentage of subjects without bactericidal activity at 1:4 dilution using the human Serum Bactericidal Assay (hSBA) against each strain in MenABCWY group and MenACWY group. The data provided is an average of the percentage of subjects without bactericidal activity at 1:4 dilution across all 110 strains.

Secondary Endpoints
Percentages of Subjects Without Bactericidal Activity at 1:4 Dilution Against Each US N. Meningitidis Serogroup B Strain at 4 Months After the 3-dose Vaccination Series.
At Month 10 (4 months after the 3-dose vaccination series)
Percentages of Subjects Without Bactericidal Activity at 1:8 Dilution Against Each US N. Meningitidis Serogroup B Strain at 1 and 4 Months After the 3-dose Vaccination Series.
At Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)
Percentages of US N. Meningitidis Serogroup B Strains Killed at 1:4 and 1:8 Dilutions at 1 and 4 Months After the 3-dose Vaccination Series
At Month 6 (before the 3-dose vaccination series) and at Months 7 and 10 (1 and 4 months after the 3-dose vaccination series)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
MenABCWY GroupEXPERIMENTALSubjects who received 2 doses of MenABCWY vaccine in the parent study and a 3rd dose of MenABCWY vaccine in the current study.
MenACWY GroupACTIVE_COMPARATORSubjects who received 1 dose of placebo and 1 dose of MenACWY vaccine in the parent study and 1 dose of placebo in the current study.
Interventions
NameTypeDescription
Meningococcal ABCWYBIOLOGICALOne dose administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
PlaceboBIOLOGICALOne dose of placebo administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
Unlock Study Design Details
Eligibility Criteria
Age Range10 Years — 19 Years
SexALL
Healthy VolunteersNo
Study Sites8

Inclusion Criteria: * Adolescents who completed V102\_16 study and received the study vaccines as assigned in the protocol (either two doses of the MenABCWY or one dose each of MenACWY and Placebo). Exclusion Criteria: * Serious, acute, or chronic illnesses. Previous or suspected disease caused b...

Countries:United States
Unlock Eligibility Criteria